COVID-19 and Adolescent Depression and Suicide Risk Screening Outcomes.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
09 2021
Historique:
accepted: 07 06 2021
pubmed: 19 6 2021
medline: 11 9 2021
entrez: 18 6 2021
Statut: ppublish

Résumé

Mental health concerns increased during the coronavirus disease 2019 pandemic, but previous studies have not examined depression screening in pediatric primary care. We aimed to describe changes in screening, depressive symptoms, and suicide risk among adolescents during the coronavirus disease 2019 pandemic. In a repeat cross-sectional analysis of electronic health record data from a large pediatric primary care network, we compared the percentage of primary care visits where adolescents aged 12 to 21 were screened for depression, screened positive for depressive symptoms, or screened positive for suicide risk between June and December 2019 (prepandemic) and June and December 2020 (pandemic). Changes were examined overall, by month, and by sex, race and ethnicity, insurance type, and income. Modified Poisson regression was used to calculate prevalence ratios (PRs) for the prepandemic to pandemic changes. Depression screening at primary care visits declined from 77.6% to 75.8% during the pandemic period (PR: 0.98, 95% confidence interval [CI]: 0.90-1.06). The percentage of adolescents screening positive for depressive symptoms increased from 5.0% to 6.2% (PR: 1.24, 95% CI: 1.15-1.34), with greater increases among female, non-Hispanic Black, and non-Hispanic white adolescents. Positive suicide risk screens increased from 6.1% to 7.1% (PR: 1.16, 95% CI: 1.08-1.26), with a 34% relative increase in reporting recent suicidal thoughts among female adolescents (PR: 1.34, 95% CI: 1.18-1.52). Results suggest that depression and suicide concerns have increased during the pandemic, especially among female adolescents. Results underscore the importance of consistent depression and suicidality screening.

Sections du résumé

BACKGROUND
Mental health concerns increased during the coronavirus disease 2019 pandemic, but previous studies have not examined depression screening in pediatric primary care. We aimed to describe changes in screening, depressive symptoms, and suicide risk among adolescents during the coronavirus disease 2019 pandemic.
METHODS
In a repeat cross-sectional analysis of electronic health record data from a large pediatric primary care network, we compared the percentage of primary care visits where adolescents aged 12 to 21 were screened for depression, screened positive for depressive symptoms, or screened positive for suicide risk between June and December 2019 (prepandemic) and June and December 2020 (pandemic). Changes were examined overall, by month, and by sex, race and ethnicity, insurance type, and income. Modified Poisson regression was used to calculate prevalence ratios (PRs) for the prepandemic to pandemic changes.
RESULTS
Depression screening at primary care visits declined from 77.6% to 75.8% during the pandemic period (PR: 0.98, 95% confidence interval [CI]: 0.90-1.06). The percentage of adolescents screening positive for depressive symptoms increased from 5.0% to 6.2% (PR: 1.24, 95% CI: 1.15-1.34), with greater increases among female, non-Hispanic Black, and non-Hispanic white adolescents. Positive suicide risk screens increased from 6.1% to 7.1% (PR: 1.16, 95% CI: 1.08-1.26), with a 34% relative increase in reporting recent suicidal thoughts among female adolescents (PR: 1.34, 95% CI: 1.18-1.52).
CONCLUSIONS
Results suggest that depression and suicide concerns have increased during the pandemic, especially among female adolescents. Results underscore the importance of consistent depression and suicidality screening.

Identifiants

pubmed: 34140393
pii: peds.2021-051507
doi: 10.1542/peds.2021-051507
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest relevant to this article to disclose.

Auteurs

Stephanie L Mayne (SL)

The Possibilities Project, Children's Hospital of Philadelphia maynes@chop.edu.
Departments of Pediatrics.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Chloe Hannan (C)

The Possibilities Project, Children's Hospital of Philadelphia.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Molly Davis (M)

Psychiatry, Perelman School of Medicine.
Penn Implementation Science Center at the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania.

Jami F Young (JF)

Center for Pediatric Clinical Effectiveness and PolicyLab.
Psychiatry, Perelman School of Medicine.
Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Mary Kate Kelly (MK)

The Possibilities Project, Children's Hospital of Philadelphia.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Maura Powell (M)

The Possibilities Project, Children's Hospital of Philadelphia.

George Dalembert (G)

The Possibilities Project, Children's Hospital of Philadelphia.
Departments of Pediatrics.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Katie E McPeak (KE)

The Possibilities Project, Children's Hospital of Philadelphia.
Departments of Pediatrics.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Brian P Jenssen (BP)

The Possibilities Project, Children's Hospital of Philadelphia.
Departments of Pediatrics.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Alexander G Fiks (AG)

The Possibilities Project, Children's Hospital of Philadelphia.
Departments of Pediatrics.
Center for Pediatric Clinical Effectiveness and PolicyLab.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH